Vir Biotechnology is handing off certain commercial rights for its hepatitis D program to European specialty pharma Norgine ...

Many racetracks have succumbed to high real-estate prices in recent years, their sweeping turns or steep banking replaced by subdivisions or warehouses. At least for now, Virginia International ...

Vir Biotechnology plans to give an exclusive license for the commercial rights to a chronic hepatitis delta treatment to an affiliate of Norgine. The biopharmaceutical company said Tuesday the license ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the efficacy results hoped for in a midstage study. The investigational combo of ...

ALTON, Va. (WFXR) – The VIRginia International Raceway (VIR) has announced this year is its 25th anniversary and is gearing up to celebrate with high-octane heart-pumping thrills all season.

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. -- Vir Biotechnology's chronic hepatitis delta ...

- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA ...

HALIFAX COUNTY, Va. (WDBJ) - A core piece of history is growing at the Virginia International Raceway. Many people don’t tend to think about trees when they’re at a racetrack, but for VIR fans, that’s ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has entered into an exclusive worldwide license agreement with Sanofi for three clinical-stage masked ...

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and ...